iRhythm Holdings, Inc. Common Stock (IRTC) Stock
Key stats
- Market cap
- $2.94B
- Price / Earnings ratio
- -75.0x
- EPS (TTM)
- -$1.16
- Volume
- Loading
- 52-week high
- $192.47
- 52-week low
- $82.85
Source: third-party data provider, as of November 13, 2026
Compare with IRTC
Recent news
iRhythm Holdings, Inc. (IRTC) Earnings Expected to Grow: Should You Buy?
iRhythm Holdings, Inc. (IRTC) Earnings Expected to Grow: Should You Buy?
IRTC
Here's Why You Should Retain IRTC Stock in Your Portfolio for Now
Here's Why You Should Retain IRTC Stock in Your Portfolio for Now
IRTC
Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?
Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?
IRTC
iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform
iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform
IRTCNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 31.14
- MACD 12/26/9
- -4.53
- EMA 9 of MACD
- -0.04
- MACD histogram
- -4.49
- SMA 50
- $112.97
- Price below SMA 50
- EMA 50
- $113.22
- Price below EMA 50
- SMA 200
- $120.17
- Price below SMA 200
- EMA 200
- $126.59
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 11 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
iRhythm Holdings, Inc. (IRTC) Earnings Expected to Grow: Should You Buy?
iRhythm Holdings, Inc. (IRTC) Earnings Expected to Grow: Should You Buy?
IRTCHere's Why You Should Retain IRTC Stock in Your Portfolio for Now
Here's Why You Should Retain IRTC Stock in Your Portfolio for Now
IRTCShould Investors Buy IRTC as Growth Improves but Risks Stay Elevated?
Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?
IRTCiRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform
iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform
IRTC
Here's Why iRhythm Holdings, Inc. (IRTC) is a Strong Momentum Stock
Here's Why iRhythm Holdings, Inc. (IRTC) is a Strong Momentum Stock
IRTC
iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised
iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised
IRTC
iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates
iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates
IRTC
iRhythm Technologies Q2 Earnings Call Highlights
iRhythm Technologies Q2 Earnings Call Highlights
IRTC
iRhythm discloses cyber incident, says no impact on device systems, patient safety
iRhythm discloses cyber incident, says no impact on device systems, patient safety
IRTC
iRhythm Technologies Touts Medicare Win, Zio Growth and AI-Driven Margin Gains
iRhythm Technologies Touts Medicare Win, Zio Growth and AI-Driven Margin Gains
IRTCNews tone: automated (AI) classification of the article's content, not a price prediction.
About iRhythm Holdings, Inc. Common Stock
iRhythm Holdings Inc formerly, iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Quentin S. Blackford | President, CEO & Director | 1979 |
| Mr. Daniel G. Wilson | CFO & Principal Financial Officer | 1982 |
| Dr. Minang P. Turakhia M.D., M.S. | Chief Medical & Scientific Officer and Executive VP of Advanced Technologies | 1974 |
| Mr. Patrick Michael Murphy J.D. | Chief Business & Legal Officer | 1979 |
| Mr. Chad M. Patterson | Chief Commercial and Product Officer | 1982 |
| Mr. Mervin Smith | Executive Vice President of Business Operations | 1975 |
| Mr. Marc Rosenbaum | Senior VP of Finance & Chief Accounting Officer | 1973 |
| Mr. Brian Lawrence | Executive VP & CTO | 1970 |
| Ms. Lisa Pecora | Senior Vice President of Finance & Investor Relations | — |
| Mr. Sean Clinton Freeman | Executive Vice President of Strategy & Corporate Development | 1976 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 31.14
- MACD 12/26/9
- -4.53
- EMA 9 of MACD
- -0.04
- MACD histogram
- -4.49
- SMA 50
- $112.97
- Price below SMA 50
- EMA 50
- $113.22
- Price below EMA 50
- SMA 200
- $120.17
- Price below SMA 200
- EMA 200
- $126.59
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
11 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $120.00
- Average
- $150.36
- High
- $206.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.3 | +10.5 | ||||||||||
| 2022 | +3.4 | +2.6 | +19.7 | -24.2 | +10.0 | -21.7 | +37.8 | -6.6 | -16.6 | -0.0 | -14.0 | -13.6 |
| 2023 | +4.5 | +15.1 | +5.0 | +6.6 | -14.1 | -5.5 | +1.0 | -0.5 | -8.0 | -14.7 | +8.1 | +20.0 |
| 2024 | +18.2 | -4.0 | -3.8 | -5.2 | -21.1 | +28.0 | -9.6 | |||||
| 2025 | -2.4 | |||||||||||
| 2026 | -18.4 | -14.1 | -8.1 | +9.3 | -5.7 | +9.0 | -5.9 | -4.6 | -7.1 | +11.1 | -31.8 |
